EXPLORING THE THERAPEUTIC POTENTIAL OF RESVERATROL AND QUERCETIN IN GASTROINTESTINAL CANCER: A NUTRITIONAL INTERVENTION APPROACH

This study examines the impacts of resveratrol and quercetin, both individually and in combination, on different cellular irregularities and biomarkers in a carefully regulated experimental paradigm. Analyzed criteria included nucleus polymorphism, mucosal stratification, loss of nuclear polarity, decreased goblet cells, crypt abnormalities, M30 tissue level, AgNORs in the core, and beta-catenin expression. The results indicate substantial differences across the groups regarding nucleus variability, mucosal categorization, loss of nuclear polarity, decreased goblet cells, and crypt abnormalities (p=0.001). This suggests that the treatments have resulted in various degrees of cellular response. Furthermore, notable disparities were noted in the M30 tissue level, AgNORs in core, and beta-catenin expression, underscoring differential modifications in cellular processes and biomarkers associated with various therapies (p<0.05). More precisely, the concurrent use of resveratrol and quercetin resulted in decreased beta-catenin expression in comparison to the other experimental groups. These findings highlight the capability of resveratrol and quercetin, both separately and together, to regulate indicators of cellular health. This has implications for therapeutic treatments aimed at addressing cellular irregularities and associated diseases. Additional research is necessary to clarify the underlying mechanisms and improve therapeutic approaches using these natural chemicals.